Prostate Cancer
Conditions
Keywords
post [177Lu]Lu-PSMA targeted therapy, PSMA-positive, mCRPC adults, Metastatic castration-resistant prostate cancer, AAA817, [225Ac]Ac-PSMA-617, PSMA-based targeted therapy, Standard of Care, SOC
Brief summary
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment
Detailed description
Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817.
Interventions
DRUGInvestigators choice of SoC
The control treatment in Phase III is investigator's choice of SoC
DRUGAAA817
The investigational treatment is AAA817
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
∙ * adults ≥ 18 years of age. * ECOG performance status of 0 to 2. * histopathological and/or cytological confirmation of adenocarcinoma of the prostate. * PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imaging agent as protocol instructed, * castrate level of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L). * Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. * ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization * eGFR as requested by the sponsor
Exclusion criteria
* Any investigational agents within 28 days prior to the day of randomization. * Any 225Ac-based investigational compound used prior to the day of randomization. * Participants with a history of CNS metastases who are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity. * Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days) or chronic kidney disease (at least 3 months of ongoing renal injury) * Baseline xerostomia ≥ Grade 2 by CTCAE v.5 * History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease * History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, non-invasive malignant colon polyps that have been removed). Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biochemical response rate (Phase II) | from date of randomization up to approximately 24 months | Biochemical response rate as defined as the percentage of participants who achieved a ≥ 50% decrease from baseline that is confirmed by a second measurement |
| Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II | from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later | Safety defined as the type, incidence and severity of AEs and SAEs, and deaths |
| Tolerability of the proposed dose of AAA817- Phase II | From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817 | Percentage of participants who experienced Dose interruptions, reductions, discontinuation, dose intensity and duration of exposure |
| Radiographic progression-free survival (rPFS)- Phase III | from date of randomization up to approximately 24 months | Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis |
| Overall survival (OS)- Phase III | from date of randomization up to approximately 24 months | Percentage of participants who are alive or who are lost to follow-up at the time of analysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Radiographic progression-free survival (rPFS)- Phase II | from date of randomization up to approximately 24 months | Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis |
| Progression free survival (PFS)- Phase II | from date of randomization up to approximately 24 months | Percentage of Participants meeting Progression Free Survival |
| Overall response rate (ORR)- Phase II | from date of randomization up to approximately 24 months | Percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) |
| Disease control rate (DCR)- Phase II | from date of randomization up to approximately 24 months | Percentage of participants with BOR of CR, PR, stable disease (SD) or non-CR/non-PD |
| Overall survival (OS)- Phase II | from date of randomization up to approximately 24 months | Percentage of participants who are alive or who are lost to follow-up at the analysis data cut-off |
| Progression free survival (PFS) -Phase III | from date of randomization up to approximately 24 months | Percentage of participants with PFS -defined as the time from date of randomization to first documented progression |
| Overall response rate (ORR)- Phase III | from date of randomization up to approximately 24 months | ORR is defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR) |
| Disease control rate (DCR) -Phase III | from date of randomization up to approximately 24 months | DCR is defined as the percentage of participants with BOR of confirmed CR, PR, stable disease (SD) or Non-CR/Non progressive disease (PD) |
| Duration of response (DoR)- Phase III | from date of randomization up to approximately 24 months | Percentage of participants with confirmed DoR defined as duration of time between the date of first documented response (CR or PR) and progression or death due to any cause, whichever occurs first. |
| Time to first radiographic soft tissue progression (TTSTP)- Phase III | from date of randomization up to approximately 24 months | Percentage of participants with confirmed first radiographic progression in soft tissue |
| First symptomatic skeletal event (TTSSE)_Phase III | from date of randomization up to approximately 24 months | Percentage of participants with confirmed skeletal event is defined as new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, or requirement for radiation therapy to relieve bone pain, or death due to any cause, whichever occurs first |
| Prostate specific antigen (PSA) response -Phase III | from date of randomization up to approximately 24 months | PSA50 is defined as the percentage of participants who achieved a confirmed ≥ 50% decrease from baseline |
| Patient reported disease related symptoms and health-related quality of life (HRQoL): Phase III | from date of randomization up to approximately 24 months | Percentage of participants who had a Change from baseline on FACT-P Prostate Cancer Subscale (PCS) |
| Time to worsening on the Worst Pain: Phase III | from date of randomization up to approximately 24 months | Time to worsening on the Worst Pain defined as the time from randomization to the first occurrence of worsening on the Worst Pain item (brief pain inventory - short form (BPI-SF)) of at least 30% of baseline or minimum of 2 points increase from baseline, or death due to any cause, whichever occurs first. BPI-SF is a self-reported questionnaire to evaluate pain intensity (severity) and impact of pain on the participant's daily functioning (interference). |
Countries
Australia, Brazil, China, Hong Kong, Israel, Japan, Singapore, South Korea, Switzerland, Taiwan, United States
Contacts
CONTACTNovartis Pharmaceuticals
Outcome results
None listed